Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 270

The DOI matches its Crossref record.

GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS

&NA;·2002·Infectious Diseases in Clinical Practice

Abstract

GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS [Department of Health and Human Services (http://www.hivatis.org)]: These are the revised guidelines from DHHS, which became official February 4, 2002. This is a “living document” so that many of the changes from the previous official release had already been posted on the HIV/AIDS Treatment Information Service web site. Highlights include the following. Who Should Be Treated? The guidelines for initiating antiretroviral therapy are somewhat more conservative based on the following observations: The infection cannot be cured with present drugs; there has been no convincing benefit to therapy when initiated before a CD4 cell count threshold of 200/mm3; treatment is associated with substantial toxicity and adherence requirements; and, treatment introduces the risk of production of resistant strains. Nevertheless, there are massive data showing the great benefit of therapy for those with more advanced disease in terms of viral suppression, immune recovery, and reduction in mortality and AIDS-associated complications. The major prognostic indicator is the CD4 cell count; viral load also influences prognosis, but is less important than the CD4 cell count. It should be emphasized that patient readiness is a critical component of the decision to initiate antiretroviral therapy. On the basis of these observations, the following recommendations are made (Table 1).TABLE 1: Who should be treated?What To Start With? Recommendations are based on data showing viral suppression in therapeutic trials with treatment-naïve patients in which the data are considered scientifically robust based on sample size, comparator (another regimen in the preferred category), adequate duration (24 weeks, but preferably 48 weeks), virologic end points (< 20–50 c/mL and < 500 c/mL), adequate analysis (intent-to-treat and as-treated analyses), description of adverse events, and accounting for all patients. Additional considerations include quality of life issues such as demands of the regimen (pill burden, food requirements, dosing frequency, etc.) and side effect profile. On the basis of these observations, the following recommendations were made (Table 2).TABLE 2: Recommended Regimens—Initial treatment (one each from column A and B)Laboratory Tests CD4 cell count should usually be monitored at 3–6 month intervals. The 95% confidence interval is 30% for the absolute count and 3% for the percentage. A plasma HIV RNA should be monitored immediately prior to therapy and again weeks after HAART with the expectation of a 1.0 log10 decrease at 2–8 weeks and < 50 c/mL by 16–20 weeks. Monitoring of viral load should take place at 3–4 month intervals. Discordance between the CD4 cell count and plasma HIV RNA is found in up to 20%; in these cases, therapeutic decisions are usually based on viral load results. Previous guidelines distinguished viral load results with RT-PCR and bDNA analyses; for the current bDNA assay (version 3.0), these two assays are considered comparable except at < 1500 c/mL. Resistance testing: This assay is recommended for virologic failure during HAART and when there is suboptimal suppression of viral load after initiation of antiretroviral therapy. Resistance testing should be “considered” in drug selection for acute HIV infection; however, it is not recommended in chronically infected patients before initiation of therapy, after discontinuation of antiretroviral agents, or when the viral load is too low for measurement (usually less than 1,000 c/mL). For information regarding interpretation of resistance mutations, see http://hiv-web.lanl.gov. Primary HIV Infection The preferred diagnostic test is HIV RNA when serology is negative or indeterminate. The decision to treat with antiretroviral agents is based on theoretical considerations; clinical trial data are limited, but supportive of treatment. Pregnancy Indications to treat are based on current guidelines, but also include any pregnant woman with HIV RNA levels exceeding 1,000 c/mL. The recommended antiretroviral regimen is identical to that recommended above for nonpregnant women, but should include the three-part ZDV regimen from the PACTG protocol 076 (ZDV starting at 14 weeks gestation and continue throughout pregnancy, IV therapy during labor, and oral administration to the newborn for the first 6 weeks). Women in the first trimester of pregnancy may wish to delay therapy until after 10–12 weeks gestation because this is the period of organogenesis. In addition, nausea and vomiting in early pregnancy may influence GI tolerance of these drugs and adherence. Nevertheless, many authorities recommend standard treatment regardless of gestational age if there are indications for HAART. Efavirenz should be avoided during the first trimester because of teratogenic effects in rhesus macaques. Hydroxyurea should also be avoided because it is a potent teratogen. The combination of ZDV and d4

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00019048-200202000-00035

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 270

Metadata

Authors
&NA;
Venue
Infectious Diseases in Clinical Practice
Published
2002-02
Volume
11
Issue
2
Pages
98-100
ISSN
1056-9103 (ISSN-L)
OpenAlex
W4239059398
Cited by
270
References
0
FWCI
4.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS. https://app.cochat.ai/papers/10.1097/00019048-200202000-00035
The paper
&NA;. (2002). GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS. Infectious Diseases in Clinical Practice. https://doi.org/10.1097/00019048-200202000-00035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.